RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that Ken Song, M.D., President and CEO of the Company, will be presenting at the 40^th Annual J.P. Morgan Healthcare Conference being held virtually on Tuesday, January 11, 2022.

J.P. Morgan Healthcare Conference

Date: Tuesday, January 11, 2022

Time: 11:00 a.m. - 11:25 a.m. EST

Please click on the below link to find additional details about the J.P. Morgan Healthcare Conference

https://www.jpmorgan.com/solutions/cib/insights/health-care-conference

About RayzeBio

RayzeBio, Inc., located in San Diego, CA, is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005175/en/